Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters








Language
Year range
1.
Chinese Pharmaceutical Journal ; (24): 144-149, 2019.
Article in Chinese | WPRIM | ID: wpr-858100

ABSTRACT

OBJECTIVE:To analyze the usage and trends of medicines for hypertension in continuous membership hospital of Chinese medicine and economic information(CMEI) network during recent 5 years and offer data and evidences for the optimization of diseases control and medical insurance policy. METHODS:The medicines structure and indexes of usage amount, DDDs, annually increasing rate were analyzed and calculated. And the usage of medicines in essential medicine list and medical insurance list were compared. The top 10 of sum and DDDs in 2017 were ranked among the hospital from different regions and different levels. RESULTS:During recent 5 years, 84 generic medicines and 256 products were used in CMEI membership hospital, among which 54 generic medicines and 203 products were in the national medical insurance list, 22 generic medicines and 42 products were in the national essential medical list. The sum and DDDs proportion structure of 5 different ATC sub-class appreciably changed during 5 years. The annual increase rate of total sum and DDDs slowed down gradually. The sum and DDDs proportion of medicine in national medical insurance list and national essential medical list were decreased annually. The top 10 produces of sum and DDDs in the hospital from different regions and levels in 2017 were concentrated. The essential medicines in the top 10 rank were fewer but took the 20.01% of the sum and 24.13% of the DDDs in 2017. CONCLUSION:Due to the hierarchical diagnosis and separation medicines sales from hospital, the increase rate of sum and DDDs of medicines for hypertension in hospital slows down gradually. The essential medicine plays an important role in hypertension treatment. The national medical insurance list and national essential medicine list should be optimized according to the clinical advantage and evidence from the newer and innovated medicines.

SELECTION OF CITATIONS
SEARCH DETAIL